H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $100 from $80 and keeps a Buy rating on the shares following the Q2 sales beat.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Positive Outlook on Rhythm Pharmaceuticals: Strong Growth Potential and Strategic Advancements Support Buy Rating
- Optimistic Buy Rating for Rhythm Pharmaceuticals Driven by Strong Sales and Promising Growth Prospects
- Rhythm Pharmaceuticals price target raised to $135 from $130 at Citizens JMP
- Rhythm Pharmaceuticals Reports Strong Q2 2025 Growth